Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's Disease
Status:
Terminated
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The effect of varenicline, an alpha4beta2 nicotinic receptor partial agonist on excessive
daytime sleepiness in Parkinson's disease will be studied in a randomized, double blind,
placebo-controlled clinical trial with a within-subject crossover design.